Section Arrow
TGTX.NASDAQ
- TG Therapeutics
Quotes are at least 15-min delayed:2024/05/17 00:26 EDT
Last
 17.42
-0.3 (-1.69%)
Day High 
17.735 
Prev. Close
17.72 
1-M High
18.41 
Volume 
2.02M 
Bid
17.45
Ask
17.42
Day Low
17.29 
Open
17.72 
1-M Low
12.93 
Market Cap 
2.74B 
Currency USD 
P/E 59.07 
%Yield
10-SMA 17 
20-SMA 15.52 
50-SMA 15.37 
52-W High 31.81 
52-W Low 6.46 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.30/0.39
Enterprise Value
2.85B
Balance Sheet
Book Value Per Share
1.04
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
233.66M
Operating Revenue Per Share
1.23
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.1001+0.0224+28.83%-- 
NBYNovaBay Pharmaceuticals0.12+0.0155+14.83%-- 
DNAGinkgo Bioworks Holdings0.839-0.0001-0.01%-- 
JAGXJaguar Health0.2867+0.0316+12.39%-- 
NVAXNovavax14.4+1.5+11.63%-- 
Quotes are at least 15-min delayed:2024/05/17 00:26 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.